Login
$AKTS
$16.16 -$0.46 (2.77%) Live

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Source
Matthew Roden, PhD Also a director
President, Chief Executive Officer and Director
55 Since 2020
6 years
Kyle D. Kuvalanka
Chief Financial Officer
57 Since 2025
1 year
Shulamit Ron-Bigger, PhD
Chief Operating Officer
45 Since 2022
4 years
Akos Czibere, MD, PhD
Chief Medical Officer
48 Since 2024
2 years
Paul L. Feldman, PhD
Chief Scientific Officer
65 Since 2020
6 years
Tyler Benedum, PhD
Chief Technical Officer
50 Since 2024
2 years

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the 10-K annual report · updated by the 8-K of Apr 16, 2026

Directors
7
serving now
Average tenure
3.5 years
from year joined
CEO also chairs the board
No
Todd Foley
Director Age On board Committees Other public boards Pay Source
Todd Foley
54 2020
6 years
None stated None stated Not stated
Matthew Roden
55 2020
6 years
None stated None stated Paid as CEO
Ken Herrmann
48 2024
2 years
None stated None stated Not stated
Lloyd M. Segal
62 2021
5 years
None stated None stated Not stated
Michael A. Sherman
59 2025
1 year
None stated Werewolf Therapeutics, Inc. (Nasdaq: HOWL) Not stated
Mary Thistle
66 2025
1 year
None stated Cullinan Therapeutics, Inc. (Nasdaq: CGEM) Not stated
Glenn Gormley Joined Apr 15, 2026
- -
Science and Technology Committee · Chair
- -

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.

No proxy statement on record

Related-party transactions come from the company’s proxy statement. Aktis Oncology, Inc. has not filed one with the SEC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support